Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate

• Published in: Cancer research (Chicago, Ill.) Vol. 54; no. 11; pp. 2923 - 2927
• Main Authors: ZVI RAM, DVORIT SAMID, WALBRIDGE, S, OSHIRO, E. M, VIOLA, J. J, JUNG-HWA TAO-CHENG, SHACK, S, THIBAULT, A, MYERS, C. E, OLDFIELD, E. H
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.1994
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Brain Neoplasms - metabolism; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Brain Neoplasms - prevention & control; Brain Neoplasms - ultrastructure; Cell Division - drug effects; Chemotherapy; Drug Screening Assays, Antitumor; Gliosarcoma - metabolism; Gliosarcoma - mortality; Gliosarcoma - pathology; Gliosarcoma - prevention & control; Gliosarcoma - ultrastructure; Medical sciences; Microscopy, Electron; Neoplasm Transplantation; Pharmacology. Drug treatments; Phenylacetates - blood; Phenylacetates - cerebrospinal fluid; Phenylacetates - therapeutic use; Rats; Rats, Inbred F344; Tumor Stem Cell Assay; Antineoplastic agent; Intracranial; Nervous system diseases; Intraperitoneal administration; Rat; Rodentia; Malignant tumor; In vitro; Biological activity; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Glioma; Animal; Central nervous system disease; Established cell line; Subcutaneous administration; Gliosarcoma; Tumor cell
• ISSN: 0008-5472; 1538-7445

Phenylacetate is a naturally occurring plasma component that suppresses the growth of tumor cells and induces differentiation in vitro. To evaluate the in vivo potential and preventive and therapeutic antitumor efficacy of sodium phenylacetate against malignant brain tumors, Fischer 344 rats (n = 50) bearing cerebral 9L gliosarcomas received phenylacetate by continuous s.c. release starting on the day of tumor inoculation (n = 10) using s.c. osmotic minipumps (550 mg/kg/day for 28 days). Rats with established brain tumors (n = 12) received continuous s.c. phenylacetate supplemented with additional daily i.p. dose (300 mg/kg). Control rats (n = 25) were treated in a similar way with saline. Rats were sacrificed during treatment for electron microscopic studies of their tumors, in vivo proliferation assays, and measurement of phenylacetate levels in the serum and cerebrospinal fluid. Treatment with phenylacetate extended survival when started on the day of tumor inoculation (P < 0.01) or 7 days after inoculation (P < 0.03) without any associated adverse effects. In the latter group, phenylacetate levels in pooled serum and cerebrospinal fluid samples after 7 days of treatment were in the therapeutic range as determined in vitro (2.45 mM in serum and 3.1 mM in cerebrospinal fluid). Electron microscopy of treated tumors demonstrated marked hypertrophy and organization of the rough endoplasmic reticulum, indicating cell differentiation, in contrast to the scant and randomly distributed endoplasmic reticulum in tumors from untreated animals. In addition, in vitro studies demonstrated dose-dependent inhibition of the rate of tumor proliferation and restoration of anchorage dependency, a marker of phenotypic reversion. Phenylacetate, used at clinically achievable concentrations, prolongs survival of rats with malignant brain tumors through induction of tumor differentiation. Its role in the treatment of brain tumors and other cancers should be explored further.